22157.jpg
Global Drug Delivery Devices Market Expected to Grow to $100.1 Billion in 2026 at a CAGR of 4.5%
July 22, 2022 06:28 ET | Research and Markets
Dublin, July 22, 2022 (GLOBE NEWSWIRE) -- The "Global Drug Delivery Devices Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global drug delivery devices market...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders
June 23, 2022 07:00 ET | Cingulate Inc.
KANSAS CITY, Kan., June 23, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate_Logo_400x400_twitter.jpg
Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational
June 17, 2022 12:45 ET | Cingulate Inc.
KANSAS CITY, Kan., June 17, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
22157.jpg
Global Drug Delivery Partnering Deals Terms and Agreements 2015-2022: Access to Over 1,500 Deal Records of Actual Deals by Company A-Z, Stage of Development, Deal Type, Therapy Focus, and Technology
June 13, 2022 04:13 ET | Research and Markets
Dublin, June 13, 2022 (GLOBE NEWSWIRE) -- The "Global Drug Delivery Partnering Terms and Agreements 2015-2022" report has been added to ResearchAndMarkets.com's offering. The Global Drug Delivery...
Cingulate_Logo_400x400_twitter.jpg
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
June 02, 2022 14:40 ET | Cingulate Inc.
KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders
May 24, 2022 06:45 ET | Cingulate Inc.
Active Pharmaceutical Ingredient – Buspirone – One of the Most Widely Prescribed Agents in $5.5B U.S. Anxiety Market, Which Must be Taken Multiple Times Daily CTx-2103 is the Third Candidate Using...
Cingulate_Logo_400x400_twitter.jpg
Cingulate to Present at H.C. Wainwright Global Investment Conference
May 18, 2022 17:20 ET | Cingulate Inc.
KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update
May 12, 2022 16:15 ET | Cingulate Inc.
KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
22157.jpg
Global Pharmaceutical Drug Delivery Markets Analysis & Forecasts, 2014-2021 & 2022-2032
April 19, 2022 05:33 ET | Research and Markets
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "Global Pharmaceutical Drug Delivery Market 2022-2032" report has been added to ResearchAndMarkets.com's offering. This recent market study on the...
API CBD Isolate VESIsorb Formulation
Geocann and Averix Bio form a strategic partnership to supply the global marketplace with pharmaceutical API phytocannabinoid ingredients formulated with a clinically proven drug delivery system technology
April 13, 2022 09:04 ET | Geocann
FORT COLLINS, Colo., April 13, 2022 (GLOBE NEWSWIRE) -- Geocann is proud to announce a strategic partnership with Averix Bio that will bring U.S.-produced API phytocannabinoid ingredients and...